AC Immune to receive milestone payment from Genentech

AC Immune to receive milestone payment from Genentech

02.11.2017 Genentech has dosed the first patient in a Phase 2 clinical trial for Alzheimer’s disease (AD) with an anti-Tau monoclonal antibody known as RO7105705. Upon the dosing of the first patient in the Phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million.

Read more…

to the press release